Leukotriene antagonists as first-line or add-on asthma-controller therapy. - Wikidata - awgldk - TriplyDB

Leukotriene antagonists as first-line or add-on asthma-controller therapy.

Leukotriene antagonists as first-line or add-on asthma-controller therapy.

http://www.wikidata.org/entity/Q48679001

about

Antileukotriene agents compared with placebo in children and adults with mild asthma Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children Addition of anti-leukotriene agents to inhaled corticosteroids in children with persistent asthma The challenge of comorbidity in clinical trials for multiple sclerosis Pharmacotherapy in the management of asthma in the elderly: a review of clinical studies Tiotropium Bromide in Chronic Obstructive Pulmonary Disease and Bronchial Asthma Real-world research and its importance in respiratory medicine The rise of multiple imputation: a review of the reporting and implementation of the method in medical research The Asthma Control Questionnaire as a clinical trial endpoint: past experience and recommendations for future use Asthma phenotypes: the intriguing selective intervention with Montelukast Lipid Mediators of Allergic Disease: Pathways, Treatments, and Emerging Therapeutic Targets Antileukotriene agents for the treatment of lung disease Guidelines for diagnosis and management of bronchial asthma: Joint ICS/NCCP (I) recommendations The leukotriene receptor antagonist montelukast and its possible role in the cardiovascular field.Challenging social cognition models of adherence: cycles of discourse, historical bodies, and interactional order.International consensus on (ICON) pediatric asthma An official American Thoracic Society research statement: comparative effectiveness research in pulmonary, critical care, and sleep medicine.Cysteinyl leukotriene receptor-1 antagonists as modulators of innate immune cell function Montelukast for the high impact of asthma exacerbations in Venezuela: a practical and valid approach for Latin America?Tiotropium in asthma: a systematic review Pediatric asthma: natural history, assessment, and treatment Reassessing the evidence hierarchy in asthma: evaluating comparative effectiveness.Is there a regulatory role of immunoglobulins on tissue forming cells relevant in chronic inflammatory lung diseases?Asthma morbidity and treatment in children with sickle cell disease.Achieving symptom control in patients with moderate asthma.Leukotriene E4 activates human Th2 cells for exaggerated proinflammatory cytokine production in response to prostaglandin D2.Clinical and cost effectiveness of mobile phone supported self monitoring of asthma: multicentre randomised controlled trial.More Effective Strategies are Needed for Elderly Asthmatics in Real-World Practice Obesity, Nutrition, and Asthma in Children.Update in asthma 2011.Side Effects of Leukotriene Receptor Antagonists in Asthmatic Children Modeling the impact of increased adherence to asthma therapy.Pharmacodynamics, pharmacokinetics and safety of GSK2190915, a novel oral anti-inflammatory 5-lipoxygenase-activating protein inhibitor.Pediatric Obesity-Related Asthma: The Role of Metabolic Dysregulation.Improving the efficiency and effectiveness of pragmatic clinical trials in older adults in the United States.Stratified approaches to the treatment of asthma.2016 Respiratory Effectiveness Group Annual Summit Report-impact & influence of real-world respiratory evidence.Long-Term Fluticasone Propionate/Formoterol Fumarate Combination Therapy Is Associated with a Low Incidence of Severe Asthma Exacerbations.Lost to follow-up in asthmatics does not mean treatment failure: causes and clinical outcomes of non-adherence to outpatient treatment in adult asthma.Pragmatic research and outcomes in asthma and COPD

P2860

Q24187545-F2E33E14-3F5C-473C-A99B-3CCE35E1A060 Q24187686-02A42AF1-FBD9-4591-8BD1-A6743F8EAB8A Q24197585-C638CD3C-5305-4ED6-88CD-FA95D60557C6 Q26765031-50390E1B-6C7A-4978-A8DF-9868D8B6A6B1 Q26769046-D789D838-E03B-40DD-B880-683769EB817D Q26780553-0166D0DA-18D7-44B8-8F33-1C057357680B Q26797460-84EA8F8A-A4FF-4D68-8C9F-5541A2488E5B Q26828889-8828AD65-DBBB-4178-8185-871FEF6391B7 Q27025354-DD1D85AF-5234-4A87-8650-4DD4F03E738E Q28071735-6A98E6AB-26EE-461D-94C7-63F44D56E947 Q28276574-349ED47A-CCDC-4DF8-B16C-F5313E4336DA Q28293842-C58CDCB7-32E4-4337-B6A3-EEB9BBAEF813 Q28392274-C66E1FF4-61C2-4C54-9AF3-40B244813C29 Q30234961-13CFA8B1-9A87-4BCE-8D22-8E2A7FA52555 Q30366913-C85A5066-DC43-4359-A460-13CB653C6F6F Q30393965-47F2670C-F5C0-4F5E-A7F9-4C40A3695530 Q33735726-6B3D9B1D-8A35-4AFF-BFD8-E1BE1FB3EAFA Q33757657-4E73ABFD-F1E9-4F8A-83BF-3C2CE5389BC3 Q34137490-AD5C6B1B-D0ED-46D5-B1B0-2ED9E0B7AF38 Q35112216-D5748731-A9CE-44DC-BE4C-7949F3E30B20 Q35211797-88323F29-2F74-4AC8-B23E-7305ECBC32EB Q35523534-7243FC43-7FCC-4F3B-A4F4-BBD1E575D8AE Q35550738-D7083BA0-E87C-406C-94CE-974B468C05A6 Q35599687-1229E628-EC39-4ED0-9309-1D1726EE2E1E Q35668375-34956863-E862-46E1-B9D7-D73F5BCE4F43 Q35738005-7AB898AE-0769-4529-95AA-A9E9326AA8A7 Q35850076-0DC71D97-5F4A-4E99-A70F-C7793F612247 Q35872116-1D9455BF-98EF-453E-BB93-8093AF3D756D Q36041393-2265E9CC-2B3F-48B2-BAE6-6FACABF0F86D Q36105881-A4E0B166-9613-46C0-97EC-40450F98E22C Q36175620-F6B36E9F-E446-43CC-B1DE-59C637769A6B Q36454156-F3DDB692-E22E-4F9A-A238-19B22C6B8858 Q36620215-AA3B1958-FE82-46A0-80A3-1D68D2265B8E Q36838183-DAAF85E8-5D4C-4031-AB5D-5E2BEE4C7E7A Q36910683-4E12EE0D-484B-4148-A380-D2C1E52A64D7 Q37064755-9C275D25-36CA-4DA6-BE0F-51D84F214AE7 Q37121292-2565C9CB-18C5-4C07-AC6C-496E7EAAA28F Q37137128-CE4A2FE2-FCDB-40E5-9C56-5D86E3A5096C Q37261427-10339663-8694-4330-945D-142924EACB85 Q37300877-9DBF849B-C92B-48C5-9966-7B37959410FD

P2860

Leukotriene antagonists as first-line or add-on asthma-controller therapy.

http://www.wikidata.org/entity/Q48679001

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh-hant

name

Leukotriene antagonists as first-line or add-on asthma-controller therapy.

@en

Leukotriene antagonists as first-line or add-on asthma-controller therapy.

@nl

type

label

Leukotriene antagonists as first-line or add-on asthma-controller therapy.

@en

Leukotriene antagonists as first-line or add-on asthma-controller therapy.

@nl

prefLabel

Leukotriene antagonists as first-line or add-on asthma-controller therapy.

@en

Leukotriene antagonists as first-line or add-on asthma-controller therapy.

@nl

P1433

Q48679001-B297F8A8-3A34-4928-9129-14FD3144CFB4

P1476

Q48679001-4843F2D8-2E28-4B9E-9A6C-1828DCD96A92

P2093

Q48679001-0A1D918E-601C-4386-9999-716BB9D9FA38

Q48679001-0B11567C-8BF6-49CB-95D4-1BC4DD5AD243

Q48679001-1C3145D0-57FF-4479-8B0E-842EF44C71D5

Q48679001-1C36715B-2EDA-4296-B94F-787EF062807C

Q48679001-3FB77FE2-FC6D-4C55-BAB0-B846D38CF131

Q48679001-5C28CEEE-BBE6-4025-9B60-48C8E904E3A5

Q48679001-5F74EE56-A6B2-433E-A773-43297207131B

Q48679001-8394005C-492E-4C66-9D9F-70C4F8CAA729

Q48679001-9A7F1BAF-1F75-45DF-A06D-236314E58B91

Q48679001-A09162D1-54AB-4750-A1C3-E1ECBAF97576

P304

Q48679001-FC7A9A2F-F019-46B0-8AA8-EABDE7BDDA42

P31

Q48679001-5F4F7BFE-1E53-43DC-B50C-C0BF560DBC8A

P356

Q48679001-C505BDD4-CBA2-4329-9DD3-F62D577D8E85

P407

Q48679001-2790A331-91B0-409C-AE4E-924A9383962F

P433

Q48679001-F64590AF-DF0F-4A8B-B719-42591E3341C3

P478

Q48679001-D041567F-E4A1-409E-91A2-142D7290672D

P50

Q48679001-066961F5-F721-46DB-B86A-119EAB6BB3E7

Q48679001-5F51C837-2F64-4E07-8023-82A77AE93100

Q48679001-992AD995-419D-476B-A54C-91B5CA3FDCE6

P577

Q48679001-FA71CFB2-6657-4055-86A1-D3C04115C4F0

P698

Q48679001-EED088C5-75FA-4170-80CE-D35FEBFAE5A9

P921

Q48679001-3569EDE0-32B9-44DD-B97C-46AC3D269BE1

P356

P1433

The New England Journal of Medicine

P1476

Leukotriene antagonists as first-line or add-on asthma-controller therapy

@en

P2093

Annie Blyth

http://www.w3.org/2001/XMLSchema#string

Daryl Freeman

http://www.w3.org/2001/XMLSchema#string

Elizabeth F Juniper

http://www.w3.org/2001/XMLSchema#string

Erika J Sims

http://www.w3.org/2001/XMLSchema#string

H Miranda Mugford

http://www.w3.org/2001/XMLSchema#string

Ian Harvey

http://www.w3.org/2001/XMLSchema#string

Jamie Murdoch

http://www.w3.org/2001/XMLSchema#string

Jon G Ayres

http://www.w3.org/2001/XMLSchema#string

Lee Shepstone

http://www.w3.org/2001/XMLSchema#string

Linda Kemp

http://www.w3.org/2001/XMLSchema#string

P304

1695-1707

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1010846

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

364

http://www.w3.org/2001/XMLSchema#string

P50

Elizabeth V Hillyer

P577

2011-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21542741

http://www.w3.org/2001/XMLSchema#string

P921